Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis
Ashot Sargsyan, Ludivine Doridot, Sarah A. Hannou, Wenxin Tong, Harini Srinivasan, Rachael Ivison, Ruby Monn, Henry H. Kou, Jonathan M. Haldeman, Michelle Arlotto, Phillip J. White, Paul A. Grimsrud, Inna Astapova, Linus T. Tsai, Mark A. Herman
Ashot Sargsyan, Ludivine Doridot, Sarah A. Hannou, Wenxin Tong, Harini Srinivasan, Rachael Ivison, Ruby Monn, Henry H. Kou, Jonathan M. Haldeman, Michelle Arlotto, Phillip J. White, Paul A. Grimsrud, Inna Astapova, Linus T. Tsai, Mark A. Herman
View: Text | PDF
Research Article Metabolism

HGFAC is a ChREBP-regulated hepatokine that enhances glucose and lipid homeostasis

  • Text
  • PDF
Abstract

Carbohydrate response element–binding protein (ChREBP) is a carbohydrate-sensing transcription factor that regulates both adaptive and maladaptive genomic responses in coordination of systemic fuel homeostasis. Genetic variants in the ChREBP locus associate with diverse metabolic traits in humans, including circulating lipids. To identify novel ChREBP-regulated hepatokines that contribute to its systemic metabolic effects, we integrated ChREBP ChIP-Seq analysis in mouse liver with human genetic and genomic data for lipid traits and identified hepatocyte growth factor activator (HGFAC) as a promising ChREBP-regulated candidate in mice and humans. HGFAC is a protease that activates the pleiotropic hormone hepatocyte growth factor. We demonstrate that HGFAC-KO mice had phenotypes concordant with putative loss-of-function variants in human HGFAC. Moreover, in gain- and loss-of-function genetic mouse models, we demonstrate that HGFAC enhanced lipid and glucose homeostasis, which may be mediated in part through actions to activate hepatic PPARγ activity. Together, our studies show that ChREBP mediated an adaptive response to overnutrition via activation of HGFAC in the liver to preserve glucose and lipid homeostasis.

Authors

Ashot Sargsyan, Ludivine Doridot, Sarah A. Hannou, Wenxin Tong, Harini Srinivasan, Rachael Ivison, Ruby Monn, Henry H. Kou, Jonathan M. Haldeman, Michelle Arlotto, Phillip J. White, Paul A. Grimsrud, Inna Astapova, Linus T. Tsai, Mark A. Herman

×

Figure 4

HGFAC-KO mice have impaired carbohydrate metabolism on HF/HS diet.

Options: View larger image (or click on image) Download as PowerPoint
HGFAC-KO mice have impaired carbohydrate metabolism on HF/HS diet.
(A) B...
(A) Body weight of male control and HGFAC-KO mice during 18 weeks of HF/HS feeding (n = 11–12/group unless otherwise specified). (B) Fat and (C) lean mass by NMR at 18 weeks. Glucose homeostasis was assessed at intervals throughout the study including (D) IP glycerol tolerance test at 4 weeks (E) IP glucose tolerance at 5 weeks, (F) IP glucose tolerance test at 13 weeks, (G) IP insulin tolerance test at 14 weeks (n = 10–11/group), and (H) a mixed meal tolerance test to assess insulin secretion at 16 weeks. Tail vein insulin levels were measured at 0 and 10 minutes. Data represent means ± SEM. Statistics were assessed by 2-tailed unpaired t test, *P < 0.05; or 2-way ANOVA with Holm-Šídák multiple comparisons between individual groups, ^P < 0.05 for comparison across genotypes within time points, $P < 0.05 for comparison across time points within genotypes.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts